

***“Understanding and engineering hematopoietic stem cells
for improved and novel cell therapies”***



Bernhard Rudolf Gentner, MD, PhD.

March 9th, 2023 9:00 am

Salón de Actos CIEMAT, Avda.Complutense 40, edificio 1

Organized by [Biomedical Innovation Unit](#).

Bernhard Rudolf Gentner

Associate Professor of Immuno-Oncology, Lausanne University Hospital, Switzerland.

Dr. Gentner is a hematologist with a clear focus on translational research in the field of gene therapy for rare diseases and cancer.

Dr. Gentner was Group Leader at San Raffaele Telethon Institute for Gene Therapy and Hematologist in the Bone Marrow Transplantation Unit, San Raffaele Hospital in Milan from 2015-2022, where his studies led to the Phase I/II first in human gene therapy study for patients affected by Mucopolysaccharidosis type 1 Hurler (Gentner et al, N Engl J Med 2021). Dr. Gentner exploited miRNA de-targeting technology to develop hematopoietic stem cell (HSC) gene therapy approaches against cancer based on the local delivery of type I or type II interferon (Escobar et al, Nat Commun 2018- co-last and corresponding author; Mucci et al, EMBO Mol Med 2021- last author). He is currently performing a clinical trial exploring HSC-based Interferon gene therapy in patients with glioblastoma multiforme.

In 2022 Dr. Gentner moved to Lausanne University Hospital where he is integrating clinical and research work to develop groundbreaking new therapies against cancer.

Registration:

Please send an email to: Israel.orman@ciemat.es including your complete name and ID number.